Title : Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.

Pub. Date : 2016 Jun

PMID : 27255535






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Based on these data, we hypothesized that the combination of the mTOR inhibitor rapamycin and the antiandrogen enzalutamide would have efficacy in LAR models. enzalutamide protein tyrosine phosphatase receptor type F Homo sapiens